Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
2017 · Cancer Research · 129 citations
https://doi.org/10.1158/0008-5472.can-16-3404
J
Junko Tanizaki
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
250
Papers
3.7K
Citations
29
h-index
50
i10-index
Junko Tanizaki is an academic researcher from Kindai University Sakai Hospital. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & HER2/EGFR in Cancer Research. The author has an h-index of 29, co-authored 213 publications.
ORCID: 0000-0002-6727-9435Papers by this author
worksDifferential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
2011 · British Journal of Cancer · 120 citations
https://doi.org/10.1038/bjc.2011.322
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification
2011 · Oncogene · 68 citations
https://doi.org/10.1038/onc.2011.111
Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
2012 · British Journal of Cancer · 58 citations
https://doi.org/10.1038/bjc.2011.586
Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with<i>HER2</i>Amplification
2010 · Molecular Cancer Therapeutics · 34 citations
https://doi.org/10.1158/1535-7163.mct-10-0045
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
2024 · Journal of Clinical Investigation · 34 citations
https://doi.org/10.1172/jci168318
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat